Skip to main content

Advertisement

SpringerLink
Log in

Management of high-risk and post-operative non-metastatic prostate cancer in Catalonia: an expert Delphi consensus

  • Research Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Background

To reach a consensus on recommendations for the management of high-risk and post-operative non-metastatic prostate cancer by a group of Radiation Oncologists in Catalonia dedicated to prostate cancer.

Methods

A modified Delphi approach was employed to reach consensus on controversial topics in Radiation Oncology on high-risk non-metastatic (eight questions) and post-operative (eight questions) prostate cancer. An agreement of at least 75% was considered as consensus. The survey was electronically sent 6 weeks before an expert meeting where topics were reviewed and discussed. A second-round survey for the controversial questions only was sent and answered by participants after the meeting.

Results

After the first round of the survey, 19 experienced Radiation Oncologists attended the meeting and 74% fulfilled the second-round online questionnaire. An agreement of 9 of the 16 questions was accounted for the first round. After the meeting, an additional agreement was reached in 3 questions leading to a final consensus on 12 of the 16 questions. There are still controversial topics like the use of PET for staging of high-risk and post-operative non-metastatic prostate cancer and the optimal dose to the prostate bed in the salvage setting.

Conclusion

This consensus contributes to establish recommendations and a framework to help in prostate cancer radiation therapy and pharmacological management in daily clinical practice of high-risk and post-operative non-metastatic prostate cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Las cifras del cáncer en España 2022. Available at: https://seom.org/images/LAS_CIFRAS_DEL_CANCER_EN_ESPANA_2022.pdf . Las consulted on 25th july 2022.

  2. Barrett D, Heale R. What are Delphi studies? Evid Based Nurs. 2020;23:68–9.

    Article  PubMed  Google Scholar 

  3. Redondo A, Oaknin A, Rubio MJ, Barretina-Ginesta M-P, de Juan A, Manso L, et al. Management of advanced ovarian cancer in Spain: an expert Delphi consensus. J Ovarian Res. 2021;14:72.

    Article  PubMed  PubMed Central  Google Scholar 

  4. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Prostate Cancer. Version 1.23. 2022.

  5. Sanda MG, Cadeddu JA, Kirkby E, Chen RC, Crispino T, Fontanarosa J, et al. Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part I: Risk Stratification, Shared Decision Making, and Care Options. J Urol. 2018;199:683–90.

  6. Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395:1208–16.

    Article  CAS  PubMed  Google Scholar 

  7. Bekelman JE, Rumble RB, Chen RC, Pisansky TM, Finelli A, Feifer A, et al. Clinically localized prostate cancer: ASCO clinical practice guideline endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline. J Clin Oncol. 2018;36:3251–8.

    Article  PubMed  Google Scholar 

  8. Nabid A, Carrier N, Martin A-G, Bahary J-P, Lemaire C, Vass S, et al. Duration of androgen deprivation therapy in high-risk prostate cancer: a randomized phase III trial. Eur Urol. 2018;74:432–41.

    Article  CAS  PubMed  Google Scholar 

  9. Attard G, Murphy L, Clarke NW, Cross W, Jones RJ, Parker CC, et al. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet. 2022;399:447–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Roach M, Moughan J, Lawton CAF, Dicker AP, Zeitzer KL, Gore EM, et al. Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial. Lancet Oncol [Internet]. 2018;19:1504–15. Available from: https://linkinghub.elsevier.com/retrieve/pii/S147020451830528X

  11. Pommier P, Chabaud S, Lagrange JL, Richaud P, Lesaunier F, Le Prise E, et al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? preliminary results of GETUG-01. J Clin Oncol. 2007;25:5366–73.

    Article  PubMed  Google Scholar 

  12. Murthy V, Maitre P, Kannan S, Panigrahi G, Krishnatry R, Bakshi G, et al. Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk prostate cancer (POP-RT): outcomes from phase III randomized controlled trial. J Clin Oncol. 2021;39:1234–42.

    Article  CAS  PubMed  Google Scholar 

  13. Ventimiglia E, Seisen T, Abdollah F, Briganti A, Fonteyne V, James N, et al. A systematic review of the role of definitive local treatment in patients with clinically lymph node-positive prostate cancer. Eur Urol Oncol. 2019;2:294–301.

    Article  PubMed  Google Scholar 

  14. Lieng H, Kneebone A, Hayden AJ, Christie DRH, Davis BJ, Eade TN, et al. Radiotherapy for node-positive prostate cancer: 2019 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group. Radiother Oncol. 2019;140:68–75.

    Article  PubMed  Google Scholar 

  15. Morris WJ, Tyldesley S, Rodda S, Halperin R, Pai H, McKenzie M, et al. Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): an analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol. 2017;98:275–85.

    Article  Google Scholar 

  16. Hoskin PJ, Rojas AM, Bownes PJ, Lowe GJ, Ostler PJ, Bryant L. Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. Radiother Oncol. 2012;103:217–22.

    Article  PubMed  Google Scholar 

  17. Kishan AU, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, et al. Radical prostatectomy, external beam radiotherapy, or external beam radiotherapy with brachytherapy boost and disease progression and mortality in patients with gleason score 9–10 prostate cancer. JAMA. 2018;319:896.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Faria S, Ruo R, Perna M, Cury F, Duclos M, Sarshoghi A, et al. Long-term results of moderate hypofractionation to prostate and pelvic nodes plus androgen suppression in high-risk prostate cancer. Pract Radiat Oncol. 2020;10:e514–20.

    Article  PubMed  Google Scholar 

  19. Morgan SC, Hoffman K, Loblaw DA, Buyyounouski MK, Patton C, Barocas D, et al. Hypofractionated radiation therapy for localized prostate cancer: An ASTRO, ASCO, and AUA evidence-based guideline. J Clin Oncol. 2018;36:3411–30.

    Article  CAS  PubMed Central  Google Scholar 

  20. Barbato F, Fendler WP, Rauscher I, Herrmann K, Wetter A, Ferdinandus J, et al. PSMA PET for the assessment of metastatic hormone-sensitive prostate cancer volume of disease. J Nucl Med. 2021;62:1747–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Emmett L, Tang R, Nandurkar R, Hruby G, Roach P, Watts JA, et al. 3-Year freedom from progression after 68 Ga-PSMA PET/CT–triaged management in men with biochemical recurrence after radical prostatectomy: results of a prospective multicenter trial. J Nucl Med. 2020;61:866–72.

    Article  CAS  PubMed  Google Scholar 

  22. Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, et al. Adjuvant radiotherapy for pathological t3n0m0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol. 2009;181:956–62.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Wiegel T, Bartkowiak D, Bottke D, Bronner C, Steiner U, Siegmann A, et al. Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96–02/AUO AP 09/95 trial. Eur Urol. 2014;66:243–50.

    Article  PubMed  Google Scholar 

  24. Hackman G, Taari K, Tammela TL, Matikainen M, Kouri M, Joensuu T, et al. Randomised trial of adjuvant radiotherapy following radical prostatectomy versus radical prostatectomy alone in prostate cancer patients with positive margins or extracapsular extension. Eur Urol. 2019;76:586–95.

    Article  PubMed  Google Scholar 

  25. Parker CC, Clarke NW, Cook AD, Kynaston HG, Petersen PM, Catton C, et al. Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial. Lancet. 2020;396:1413–21.

    Article  CAS  PubMed  Google Scholar 

  26. Kneebone A, Fraser-Browne C, Duchesne GM, Fisher R, Frydenberg M, Herschtal A, et al. Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial. Lancet Oncol. 2020;21:1331–40.

  27. Sargos P, Chabaud S, Latorzeff I, Magné N, Benyoucef A, Supiot S, et al. Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial. Lancet Oncol. 2020;21:1341–52.

    Article  CAS  PubMed  Google Scholar 

  28. Carrie C, Magné N, Burban-Provost P, Sargos P, Latorzeff I, Lagrange J-L, et al. Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial. Lancet Oncol. 2019;20:1740–9.

    Article  CAS  PubMed  Google Scholar 

  29. Shipley WU, Seiferheld W, Lukka HR, Major PP, Heney NM, Grignon DJ, et al. Radiation with or without antiandrogen therapy in Recurrent Prostate Cancer. N Engl J Med. 2017;376:417–28.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Spratt DE, McHugh DJ, Morris MJ, Morgans AK. Management of Biochemically Recurrent Prostate Cancer: Ensuring the Right Treatment of the Right Patient at the Right Time. Am Soc Clin Oncol Educ B. 2018;355–62.

  31. Parker CC, Clarke A, Cook A, Catton C, Cross WR, Kynaston H, Logue J, Petersen PM, Neville P, Persad R, Payne H, Saad F, Stirling A, Parulekar WR, Parmar MK, Sydes MR. LBA9 - Duration of androgen deprivation therapy (ADT) with post-operative radiotherapy (RT) for prostate cancer: First results of the RADICALS-HD trial (ISRCTN40814031). Ann Oncol. 2022;33:S808–69.

    Article  Google Scholar 

  32. Ghadjar P, Hayoz S, Bernhard J, Zwahlen DR, Hölscher T, Gut P, et al. Dose-intensified versus conventional-dose salvage radiotherapy for biochemically recurrent prostate cancer after prostatectomy: the SAKK 09/10 randomized phase 3 trial. Eur Urol. 2021;80:306–15.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

We want to thank the Council of Vila-Sana (Lleida) and IPSEN pharma for its support during the meeting. The authors also want to thank Magda Font and Kathryn Gibson for their language support.

Author information

Authors and Affiliations

  1. Radiation Oncology, Hospital Universitari Arnau de Vilanova, Lleida, Spain

    Marta Bonet, David González, José-Enrique Baquedano, Elena García & Moisés Mira

  2. Radiation Oncology, Hospital Universitari Vall d’Hebron, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain

    Manuel Altabas & Xavier Maldonado

  3. Radiation Oncology, Hospital Clínic, ICMHO (Institut Clínic de Malalties Hematològiques i Oncològiques), Barcelona, Spain

    Francesc Casas & Joel Mases

  4. Radiation Oncology, Consorci Sanitari de Terrassa, Hospital de Terrassa, Terrassa, Spain

    Nicolás Feltes & Joan Lozano

  5. Radiation Oncology, Institut Català d’Oncologia, Hospital Duran i Reynals, Hospitalet de Llobregat, Barcelona, Spain

    Ferran Ferrer

  6. Radiation Oncology, Parc de Salut Mar, Barcelona, Spain

    Palmira Foro & Ismael Membrive

  7. Radiation Oncology, Institut Català d’Oncologia, Hospital Josep Trueta, Barcelona, Spain

    Rafael Fuentes & Àlvar Roselló

  8. Radiation Oncology, Consorci Sanitari de Terrassa, Fundació Althaia, Manresa, Spain

    Manuel Galdeano & Saturio Paredes

  9. Radiation Oncology, Hospital Sant Joan de Reus, Reus, Tarragona, Spain

    David Gomez & Ivan Henriquez

  10. Radiation Oncology, Institut Català d’Oncologia, Hospital Can Ruti, Badalona, Spain

    Josep Jové

  11. Radiation Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

    Gemma Sancho

Authors
  1. Marta Bonet
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David González
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. José-Enrique Baquedano
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Elena García
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Manuel Altabas
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Francesc Casas
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Nicolás Feltes
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ferran Ferrer
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Palmira Foro
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Rafael Fuentes
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Manuel Galdeano
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. David Gomez
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Ivan Henriquez
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Josep Jové
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Joan Lozano
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Xavier Maldonado
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Joel Mases
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Ismael Membrive
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Saturio Paredes
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Àlvar Roselló
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. Gemma Sancho
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. Moisés Mira
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marta Bonet.

Ethics declarations

Conflict of Interest

The authors certify that they have no affiliations with or involvement in any organization or entity with any financial or non-financial interest in the subject matter or materials discussed in this manuscript.

Ethical approval

All authors have been personally and actively involved in substantial work leading to the paper, and will take public responsibility for its content.

Informed consent

The manuscript doesn’t involve patients and no experiments on human subjects have been done. An informed consent does not apply for this work.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bonet, M., González, D., Baquedano, JE. et al. Management of high-risk and post-operative non-metastatic prostate cancer in Catalonia: an expert Delphi consensus. Clin Transl Oncol 25, 1017–1023 (2023). https://doi.org/10.1007/s12094-022-03005-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-022-03005-4

Keywords

Search

Navigation